Dr. Caramori is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
9300 Euclid Avenue
F20
Cleveland, OH 44106- Is this information wrong?
Summary
- Dr. Luiza Caramori is an endocrinologist at Cleveland Clinic in OH. She is also an Adjunct Associate Professor at the University of Minnesota. Dr. Caramori received her medical degree from Federal University of Rio Grande do Sul School of Medicine, completed over 14 years of training after medical school, including residency, fellowships, Masters, PhD and Post-PhD. She has been in practice for 32 years. Dr. Caramori speaks multiple languages, including Portuguese. She is a clinician-scientistist funded by NIH, and an internationally recognized expert in diabetic kidney disease. Her clinical interest focuses on diabetic kidney disease, type 1 diabetes, and type 2 diabetes. She provides outstanding care to her patients.
Education & Training
University of MinnesotaFellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2006
Federal University of Rio Grande do Sul School of MedicineClass of 1990
Certifications & Licensure
OH State Medical License 2022 - 2026
MN State Medical License 2006 - 2023
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes Start of enrollment: 2014 Feb 01
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease Start of enrollment: 2015 Sep 17
- Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease Start of enrollment: 2015 Sep 17
Publications & Presentations
PubMed
- 5 citationsEfficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.Tuttle, K., Hauske, S., Canziani, M., Caramori, M., Cherney, D., Cronin, L., Heerspink, H., Hugo, C., Nangaku, M., Rotter, R., Silva, A., Shah, S., Sun, Z., Urbach, D....> ;Lancet. 2024 Jan 27
- 2 citationsEffects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin ...Janet B McGill, Rajiv Agarwal, Stefan D Anker, George L Bakris, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Andreas L Birkenfeld, Maria L Caramori, Meike Brink...> ;Diabetes, Obesity & Metabolism. 2023 Jun 1
- 156 citationsSerum Urate Lowering with Allopurinol and Kidney Function in Type 1 DiabetesAlessandro Doria, Andrzej T. Galecki, Cathie Spino, Rodica Pop-Busui, David Z.I. Cherney, Ildiko Lingvay, Afshin Parsa, Peter Rossing, Ronald J. Sigal, Maryam Afkarian...> ;The New England Journal of Medicine. 2020 Jun 25
- Join now to see all
Press Mentions
U of M Awarded $2.5M in NIH Funding for Minnesota Site of Kidney Precision Medicine ProjectNovember 3rd, 2022
Professional Memberships
- Chair - Diabetic Nephropathy Subcommittee for the ADA Annual Scientific Sessions 2018-2020
- Member
- Member
- European Diabetic Nephropathy Study GroupMember
Other Languages
- Portuguese
Hospital Affiliations
M Health Fairview University of Minnesota Medical CenterMinneapolis, Minnesota
Cleveland ClinicCleveland, Ohio
M Health Fairview Southdale HospitalMinneapolis, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
